RxDoctor Payments Data

Catherine Krings

Family · Surprise, AZNPI 1053628925

Payments from drug & device makers

$1,521in general payments, 2019–2025

Across 82 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$384
  • Boston Scientific$154
  • Novo Nordisk$125
  • AbbVie$125
  • Pfizer$112
  • Lilly USA, LLC$101
  • plus $520 from 16 others

What the payments were for

  • Food & beverage$1,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,521 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$5,369
Medicare patients
37
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$63,274
OzempicSemaglutide39$45,028
FarxigaDapagliflozin Propanediol30$39,952
EliquisApixaban17$24,885
JanuviaSitagliptin Phosphate12$16,287
JardianceEmpagliflozin14$8,424
Liothyronine Sodium47$2,964
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,546
Albuterol Sulfate HfaAlbuterol Sulfate59$1,909
Levothyroxine Sodium249$1,868
SynthroidLevothyroxine Sodium22$1,706
Atorvastatin Calcium173$1,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,506
Ezetimibe36$1,428
Lisinopril183$1,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$101$63,27454 claims
Novo NordiskOzempic$125$45,02839 claims
AstraZenecaFarxiga$384$39,95230 claims
PfizerEliquis$112$24,88517 claims
AbbVieSynthroid$125$1,70622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →